Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018
January 02 2018 - 4:30PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that the Company is scheduled to present at the J.P.
Morgan 2018 Healthcare Conference in San Francisco on Tuesday,
January 9, 2018 at 11:30 a.m. PT (2:30 p.m. ET), followed by a
Q&A session.
A live webcast of the presentation and Q&A session can be
accessed on the investor page of Sage's website at
investor.sagerx.com. A replay of the webcast will also be archived
for up to 30 days on Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders.
Sage has a portfolio of novel product candidates targeting critical
CNS receptor systems, GABA and NMDA. Sage's lead program, a
proprietary IV formulation of brexanolone (SAGE-547), has completed
two Phase 3 clinical trials in postpartum depression. Sage is
developing its next generation modulators, including SAGE-217 and
SAGE-718, in various CNS disorders. For more information, please
visit www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180102005782/en/
Sage TherapeuticsInvestor Contact:Paul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Maureen L.
Suda, 585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024